(SPH) Sopharma AD - Ratings and Ratios

Sopharma AD is a Bulgarian pharmaceutical company with a diverse product portfolio and a significant presence in Europe. The company operates through multiple business segments, including production and distribution of pharmaceutical products, as well as other activities such as contract manufacturing and real estate leasing. Sopharma ADs product offerings include a range of pharmaceuticals, medical devices, food supplements, and medicinal cosmetics.

The companys product portfolio includes well-established brands such as Carsil, Tabex, and Tribestan, which are used to treat various health conditions. Sopharma AD also provides a range of services, including packaging and product development, and engages in trading and distribution of pharmaceuticals and medical supplies. With a history dating back to 1933, the company has established itself as a major player in the Bulgarian pharmaceutical market.

From a financial perspective, Sopharma AD has a market capitalization of 2312.02M PLN, indicating a significant market presence. The companys P/E ratio of 13.68 and forward P/E ratio of 10.21 suggest a relatively attractive valuation. Additionally, the companys RoE of 9.76% indicates a decent return on equity. To further evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating margin should be monitored. For instance, a high revenue growth rate and stable gross margin could indicate a strong competitive position, while a high operating margin could suggest efficient cost management.

Some key metrics to monitor for Sopharma AD include its dividend yield, debt-to-equity ratio, and interest coverage ratio. A stable dividend yield could indicate a commitment to returning value to shareholders, while a low debt-to-equity ratio and high interest coverage ratio could suggest a healthy balance sheet. By analyzing these KPIs, investors can gain a deeper understanding of Sopharma ADs financial health and competitive position, and make more informed investment decisions.